PT - JOURNAL ARTICLE AU - Nadia M Ikumi AU - Thokozile R Malaba AU - Komala Pillay AU - Marta C Cohen AU - Hlengiwe P Madlala AU - Mushi Matjila AU - Dilly Anumba AU - Landon Myer AU - Marie-Louise Newell AU - Clive M Gray AU - for the PIMS Study Group TI - Associating antiretroviral therapy initiated before or during pregnancy with placenta pathology in HIV infected women AID - 10.1101/2020.06.15.20131615 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.15.20131615 4099 - http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131615.short 4100 - http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131615.full AB - Background Antiretroviral therapy (ART) is universally recommended for all HIV-infected pregnant women to improve survival and to reduce mother-to-child HIV transmission. With widespread use of ART in areas of high HIV prevalence, there is concern that prolonged in-utero ART exposure may result in adverse birth outcomes, such as preterm delivery and low birthweight infants. Underlying drivers of these effects may be found in the placenta.Objective We examined whole placentas from live births to seek an association between timing of ART initiation and pregnancy outcome.Study Design This was a nested sub-study in a larger cohort of HIV-infected women recruited in a large primary care antenatal clinic in Cape Town, South Africa. Whole placentas (n=130) were collected at delivery and examined for histopathology from two ART groups. The stable group (n=53) initiated ART prior to pregnancy and the initiating group (n=77) started ART at a median of 15 weeks gestation. Adverse birth outcomes were defined by preterm delivery (PTD; n=9), small-for-gestational age (SGA; n=12) and low birthweight (LBW; n=11) in the two groups. Wilcoxon rank-sum and t-tests were used to measure differences in placental histopathology by ART group. Binomial and univariate linear regression models, chi-squared or Fisher’s exact test were used to quantify associations between placenta histopathology and maternal factors including ART timing and the association with pregnancy outcome.Results Women in the stable group were significantly older (median [IQR] 33 years [28 - 37] vs 28 [25 - 32]; p=0.003), had higher CD4 cell counts 455 cells/ml [381 - 602] vs 369.5 [251 - 534.5], p=0.04) and were less likely to be prehypertensive or hypertensive at first antenatal care visit (p=0.03) than women in the initiating group. Overall, 119 (91%), women were on a fixed dose regimen of Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV) and only 3 (2%; all in the stable group) were on a protease inhibitor (PI)-based regimen with no difference between the groups. Overall, nearly a third of placentas were small, although the fetal-placenta weight ratio was in the normal range for most women. Meconium exposure and chorioamnionitis was seen in 19% and 15% of placentas, respectively. Apart from maternal vascular malperfusion (MVM) and decidual arteriopathy, histopathology obervations did not differ significantly between stable and initiating groups. Placentas from the stable group showed increased MVM (39.6% vs 19.4%, p=0.01) and decidual arteriopathy (11.3% vs 1.3%, p=0.02), with a trend of decreased placental weight (392g vs 422g, p=0.09). MVM, in turn, was significantly associated with PTD and LBW (p=0.002 and p<0.0001) and association with SGA was borderline significant (p=0.09).Conclusion ART initiation prior to pregnancy was associated with an increased risk of maternal vascular malperfusion and decidual arteriopathy, suggestive of placental dysfunction. The association between MVM with PTD and LBW suggests that a placenta-mediated mechanism may link the putative association between ART and adverse birth outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number R01 HD080385 (PIMS Prematurity Immunology in HIV-Infected Infants and their Infants Study) National Institute for Health Research (NIHR) (17/63/26) using UK Government aid to support global health research and by the Academy of Medical Sciences networking grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Cape Town, Faculty of Health Sciences Human Research Ethics Committee (UCT-HREC) project #739/2014 University of Southampton Faculty of Medicine Ethics Committee project # 12542 PIMSAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data collected in this study will be available to external investigators interested in collaboration upon submission and approval of a data analysis plan. Requests for data available within PIMS or to submit a request for additional data collection should be submitted to M.Newell{at}soton.ac.uk and Landon.Myer{at}uct.ac.za and will be reviewed by the study steering committee